Lifecore Biomedical, Inc. (LFCR)
| Market Cap | 275.47M |
| Revenue (ttm) | 128.44M |
| Net Income (ttm) | 6.54M |
| Shares Out | 36.83M |
| EPS (ttm) | 0.17 |
| PE Ratio | 52.13 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 344,755 |
| Open | 7.12 |
| Previous Close | 7.09 |
| Day's Range | 7.09 - 7.49 |
| 52-Week Range | 3.68 - 8.90 |
| Beta | 0.94 |
| Analysts | Buy |
| Price Target | 8.00 (+6.95%) |
| Earnings Date | Oct 4, 2024 |
About LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot stud... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for LFCR stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 6.95% from the latest price.
News
Lifecore Biomedical to Present at Stephens Annual Investment Conference
CHASKA, Minn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...
Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024
CHASKA, Minn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...
Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operations
Brings Strong Background in Pharmaceutical Manufacturing Operations and Finance to Help Drive Performance and Productivity
Johnson Fistel LLP Investigates Lifecore Biomedical, Inc's Directors and Officers for Breach of Fiduciary Duties and Encourages Long Term Shareholders to Reach Out for Their Options
SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officer...
Lifecore Biomedical, Inc. (LFCR) Q1 2025 Earnings Call Transcript
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q1 2025 Earnings Call Transcript October 4, 2024 8:30 AM ET Company Participants Stephanie Diaz - Manager of IR Paul Josephs - President and CEO Ryan Lake - CF...
Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update
-- Recorded Revenues of $24.7 Million for Q1 Fiscal 2025 -- -- Signed Multiple New Business Agreements with New and Existing Customers --
Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock
PIPE with New and Existing Investors Supports Working Capital and Operations PIPE with New and Existing Investors Supports Working Capital and Operations
Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024
CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...
Lifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology
Multi-Million Dollar Development Agreement Establishes Lifecore as Lindy Biosciences' Preferred CDMO
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("...
Lifecore Biomedical, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Invited To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("...
FINAL DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options NEW YORK...
The Schall Law Firm Urges Investors To Join A Securities Fraud Case Against Lifecore Biomedical Inc
LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("...
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events
CHASKA, Minn., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announce...
Lifecore Biomedical, Inc. Is Being Sued For Violating Securities Laws And Shareholders Are Invited To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("...
The Schall Law Firm Urges Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc
LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("...
Lifecore Biomedical, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 27, 2024 Deadline to file Lead Plaintiff Motion
Investors can contact the law firm at no cost to learn more about recovering their losses
Lifecore Biomedical, Inc. Is Being Sued For Possible Securities Law Violations And Shareholders Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("...
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you su...
Lifecore Biomedical, Inc. Is Being Sued For Securities Related Infractions And Impacted Stockholders Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("...
The Schall Law Firm Encourages Investors To Take Part In A Case Against Lifecore Biomedical Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("...
Lifecore Biomedical, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Help The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("...
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options
Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational
Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges
The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc
LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("...